As expected, the proportion of sensor-based blood glucose monitoring in participants with type 2 diabetes in this study (12.0 %) is considerably lower than in the study of diabetologists in 2023 for people with insulin-dependent type 1 diabetes (77.3 %) [50] or on the basis of registry data for 2019 for children and adolescents with insulin-dependent type 1 diabetes (69.3 %) [61]. The gene discussed is INS; the disease is type 2 diabetes mellitus.